Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus NALLPEN.
NAFCILLIN SODIUM vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic